ES2173871T3 - Tratamiento de condiciones neurologicas por un compuesto inhibidor de la interleukina-1. - Google Patents
Tratamiento de condiciones neurologicas por un compuesto inhibidor de la interleukina-1.Info
- Publication number
- ES2173871T3 ES2173871T3 ES92922537T ES92922537T ES2173871T3 ES 2173871 T3 ES2173871 T3 ES 2173871T3 ES 92922537 T ES92922537 T ES 92922537T ES 92922537 T ES92922537 T ES 92922537T ES 2173871 T3 ES2173871 T3 ES 2173871T3
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- pct
- interleukina
- inhibitor compound
- neurological conditions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4721—Lipocortins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE PRESENTA EL USO DE UN COMPUESTO QUE EVITA, INHIBE O MODIFICA LA ACCION DE LA INTERLEUQUINA-1 COMO AGENTE ACTIVO PARA EL TRATAMIENTO DE CONDICIONES DE DEGENERACION NECROLOGICA. EL AGENTE ACTIVO PUEDE SER UN ANTAGONISTA RECEPTOR DE LA IL-1 PARTICULARMENTE RA DE LA IL-1 RECOMBINANTE.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919123161A GB9123161D0 (en) | 1991-10-31 | 1991-10-31 | Treatment of neurological conditions |
GB919125670A GB9125670D0 (en) | 1991-11-30 | 1991-11-30 | Treatment of neurogical conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2173871T3 true ES2173871T3 (es) | 2002-11-01 |
Family
ID=26299779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES92922537T Expired - Lifetime ES2173871T3 (es) | 1991-10-31 | 1992-11-02 | Tratamiento de condiciones neurologicas por un compuesto inhibidor de la interleukina-1. |
Country Status (10)
Country | Link |
---|---|
US (1) | US6090775A (es) |
EP (1) | EP0610336B1 (es) |
JP (1) | JP3623501B2 (es) |
AT (1) | ATE214939T1 (es) |
AU (3) | AU2884592A (es) |
CA (1) | CA2122596C (es) |
DE (1) | DE69232516T2 (es) |
DK (1) | DK0610336T3 (es) |
ES (1) | ES2173871T3 (es) |
WO (2) | WO1993008819A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6159460A (en) * | 1988-05-27 | 2000-12-12 | Amgen Inc. | Method for treating interleukin-1 mediated diseases |
US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
US6858409B1 (en) | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
ATE270550T1 (de) * | 1995-04-07 | 2004-07-15 | Teijin Ltd | Wirkstoff zum schutz für organ oder gewebe |
US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
US20030040660A1 (en) * | 2001-08-27 | 2003-02-27 | George Jackowski | Method for diagnosing and distinguishing traumatic brain injury and diagnostic devices for use therein |
WO2003022213A2 (en) * | 2001-09-06 | 2003-03-20 | Board Of Regents, The University Of Texas System | Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor |
EP1863847A2 (en) * | 2004-12-02 | 2007-12-12 | Domantis Limited | Anti-il-1r1 single domain antibodies and therapeutic uses |
BRPI0619224A2 (pt) * | 2005-12-01 | 2017-06-20 | Domantis Ltd | monômero de anticorpo de domínio, ligando, ácidos nucleicos isolado e recombinante, vetor, célula hospedeira, método para produzir um monômero de dab de ligando, composição farmacêutica, dispositivo de liberação de medicamento, uso de um monômero de anticorpo de domínio, e, método para tratar uma doença inflamatória, artrite ou doença respiratória |
AU2010203425B2 (en) * | 2009-01-09 | 2015-04-09 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of corneal disorders |
EP2598526B1 (en) | 2010-07-29 | 2018-09-05 | Eleven Biotherapeutics, Inc. | Chimeric il-1 receptor type i agonists and antagonists |
DK2968468T3 (en) | 2013-03-13 | 2021-07-26 | Buzzard Pharmaceuticals AB | Chimeric cytokine formulations for ocular delivery |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4965271A (en) * | 1986-12-31 | 1990-10-23 | Hoechst Roussel Pharmaceuticals, Inc. | Method of inhibiting the activity of leukocyte derived cytokines |
IL100535A (en) * | 1986-12-31 | 1994-05-30 | Hoechst Roussel Pharma | Pharmaceutical preparations containing a history of xanthine to relieve disease states |
HU203198B (en) * | 1987-10-26 | 1991-06-28 | Sandoz Ag | Process for producing pharmaceutical compositions having immunity-inhibiting, monokin-, particularly interleukin-1-inhibiting effect |
AU5921890A (en) * | 1989-06-13 | 1991-01-08 | Smithkline Beecham Corporation | Monokine activity interference |
AU649245B2 (en) * | 1990-04-02 | 1994-05-19 | Amgen, Inc. | Methods for treating interleukin-1 mediated diseases |
-
1992
- 1992-11-02 CA CA002122596A patent/CA2122596C/en not_active Expired - Lifetime
- 1992-11-02 AU AU28845/92A patent/AU2884592A/en not_active Abandoned
- 1992-11-02 DK DK92922537T patent/DK0610336T3/da active
- 1992-11-02 JP JP50826093A patent/JP3623501B2/ja not_active Expired - Lifetime
- 1992-11-02 ES ES92922537T patent/ES2173871T3/es not_active Expired - Lifetime
- 1992-11-02 EP EP92922537A patent/EP0610336B1/en not_active Expired - Lifetime
- 1992-11-02 US US08/232,167 patent/US6090775A/en not_active Expired - Lifetime
- 1992-11-02 WO PCT/GB1992/002019 patent/WO1993008819A1/en active Application Filing
- 1992-11-02 WO PCT/GB1992/002023 patent/WO1993008820A1/en active IP Right Grant
- 1992-11-02 AT AT92922537T patent/ATE214939T1/de not_active IP Right Cessation
- 1992-11-02 DE DE69232516T patent/DE69232516T2/de not_active Expired - Lifetime
- 1992-11-02 AU AU28041/92A patent/AU2804192A/en not_active Abandoned
-
1996
- 1996-12-24 AU AU76482/96A patent/AU7648296A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6090775A (en) | 2000-07-18 |
AU7648296A (en) | 1997-02-13 |
DK0610336T3 (da) | 2002-07-22 |
JPH07505608A (ja) | 1995-06-22 |
WO1993008820A1 (en) | 1993-05-13 |
EP0610336B1 (en) | 2002-03-27 |
JP3623501B2 (ja) | 2005-02-23 |
DE69232516D1 (de) | 2002-05-02 |
ATE214939T1 (de) | 2002-04-15 |
WO1993008819A1 (en) | 1993-05-13 |
AU2804192A (en) | 1993-06-07 |
CA2122596C (en) | 2008-06-03 |
CA2122596A1 (en) | 1993-05-13 |
EP0610336A1 (en) | 1994-08-17 |
DE69232516T2 (de) | 2002-10-31 |
AU2884592A (en) | 1993-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1334731T3 (da) | Forebyggende eller terapeutisk middel mod psoriasis omfattende anti-IL-6-receptorantistof som aktiv bestanddel | |
PT750618E (pt) | Derivados de oxazolidinona e composicoes farmaceuticas que os contem | |
ES2173871T3 (es) | Tratamiento de condiciones neurologicas por un compuesto inhibidor de la interleukina-1. | |
DK0897726T3 (da) | Antipruritisk middel | |
ES2113652T3 (es) | Pamoato de risperidona. | |
EP1108435A4 (en) | MEANS FOR PREVENTING OR TREATING PANCREATITIS CONTAINING THE IL-6 ANTAGONISTS AS ACTIVE COMPONENTS | |
SE9604793D0 (sv) | New polymorphs | |
ES2161785T3 (es) | Emplasto para el tratamiento de micosis ungulares. | |
PT804252E (pt) | Agentes queladores metalicos que contem monoaminas diamidas e tiois | |
NO996287L (no) | Chalkoner med antiproliferativ aktivitet | |
ATE332145T1 (de) | Arzneien zur begleitenden behandlung von glaukomen | |
TR199701497T1 (xx) | Beyin �demini �nleyen terkip. | |
FR2690847B1 (fr) | Compositions a activite agoniste des recepteurs analogues a 5ht1 selective. | |
ITMI920955A1 (it) | Idrogeli di tipo polietereammidoamminico come materiali eparinizzabili | |
EP1238669A3 (en) | Neutrophil function inhibitors which contain glucosamine | |
MX9304075A (es) | Composicion farmaceutica para el tratamiento o profilaxis de los desordenes trombohemorragicos consuntivos. | |
HUT73231A (en) | Pharmaceutical compositions with 17-beta-monosubstituted-carbamoyl-4-aza-5-alpha-androst-1-en-3-ones for treatment of chronic prostatitis | |
DE59303446D1 (de) | Neue bis-phenyl-hexene | |
ATE267194T1 (de) | Medikamente geeignet zur behandlung von proliferativen erkrankungen | |
ES2170807T3 (es) | Uso de prostaglandinas para la fabricacion de un medicamento para la prevencion y el tratamiento de catarata secundaria. | |
ES2136615T3 (es) | Nuevos inhibidores de glucohidrolasa utiles como agentes antidiabeticos, antiviricos y antimetastasicos. | |
ES2102370T3 (es) | Composicion antiparasitaria para uso animal. | |
EP0645963A4 (es) | ||
DE69932434D1 (de) | Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten | |
ES2098119T3 (es) | Nuevas triazoloquinazolinas, su obtencion y empleo. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 610336 Country of ref document: ES |